Fig. 3From: Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot studyProgression-free survival stratified by the RECIST and CT morphologic response. A Progression-free survival stratified by the RECIST; B. Progression-free survival stratified by the CT morphologic responseBack to article page